Anjarium Biosciences Raises $61M in Series A Financing
Summary
Anjarium Biosciences AG, a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies, closed a CHF55.5M ($61M) Series A financing. The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). In conjunction with Anjarium’s Series A financing, Dr. Bali Muralidhar of Abingworth, Dr. Bram Vanparys of Gimv and Dr. Dina Chaya of Omega Funds will join the company’s Board of Directors. The company intends to use the funds to expand its team, advance its platform and progress several therapeutic pipeline programs towards clinical development. The company’s platform combines proprietary DNA-based gene vectors, natural and synthetic nanoparticle delivery modalities – including its novel Hybridosome™ technology – and scalable manufacturing solutions.
Funding
Review available funding amount, funding date, investors, and linked company information related to Anjarium Biosciences Raises $61M in Series A Financing in the interactive ISVWorld profile.